TRiCares begins US IDE pivotal trial of TTVR system
TRiCares SAS has enrolled and treated the first patient in its TRICURE US IDE pivotal study of the Topaz transcatheter…
10 Jul 2026
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
Quoin Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for QRX003, enabling it to initiate a Phase II clinical…
10 Jul 2026
Apertura and NIH institutes to test gene therapy for NPC1
Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy to treat Niemann-Pick Disease Type C1 (NPC1). The company signed the agreement…
09 Jul 2026
Philips expands ultrasound portfolio with AI-driven Alturion
Philips has expanded its ultrasound portfolio with the launch of the Alturion system, which features AI-powered workflows and is intended for high-volume clinical environments. The product is now available in…
09 Jul 2026
First patient receives Forzinity in Mighty Therapeutics’ Phase IV study
Mighty Therapeutics has dosed the first patient in 4TAZPower, its global Phase IV confirmatory study assessing Forzinity (elamipretide) injection in those aged at least five years with Barth syndrome. The…
09 Jul 2026
Evogene and Tel Aviv University launch drug discovery initiative
Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating from Israeli academic research.…
08 Jul 2026
First patient enrolled in AtaCor’s ALARION-EV trial of EV-ICD system
AtaCor Medical has enrolled the first patient in its ALARION-EV pivotal trial, which is evaluating an investigational extravascular implantable cardioverter-defibrillator (EV-ICD) system. The study is designed for patients who need…